DE

418.13

-6.51%ā†“

FDX

209.86

-2.63%ā†“

PAYX

143.22

-6.79%ā†“

CPRT

54.49

-3.76%ā†“

HEICA

190.52

-6.49%ā†“

DE

418.13

-6.51%ā†“

FDX

209.86

-2.63%ā†“

PAYX

143.22

-6.79%ā†“

CPRT

54.49

-3.76%ā†“

HEICA

190.52

-6.49%ā†“

DE

418.13

-6.51%ā†“

FDX

209.86

-2.63%ā†“

PAYX

143.22

-6.79%ā†“

CPRT

54.49

-3.76%ā†“

HEICA

190.52

-6.49%ā†“

DE

418.13

-6.51%ā†“

FDX

209.86

-2.63%ā†“

PAYX

143.22

-6.79%ā†“

CPRT

54.49

-3.76%ā†“

HEICA

190.52

-6.49%ā†“

DE

418.13

-6.51%ā†“

FDX

209.86

-2.63%ā†“

PAYX

143.22

-6.79%ā†“

CPRT

54.49

-3.76%ā†“

HEICA

190.52

-6.49%ā†“

Search

India Globalization Capital Inc

Gesloten

0.27

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.26

Max

0.27

Belangrijke statistieken

By Trading Economics

Inkomsten

-112K

-1.8M

Verkoop

-155K

257K

Winstmarge

-711.673

Werknemers

67

EBITDA

-263K

-1.9M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+1474.07% upside

Dividenden

By Dow Jones

Volgende Winsten

20 jun 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

23M

Vorige openingsprijs

0.27

Vorige sluitingsprijs

0.27

India Globalization Capital Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 sep 2024, 04:00 UTC

Top Nieuws

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

Peer Vergelijking

Prijswijziging

India Globalization Capital Inc Prognose

Koersdoel

By TipRanks

1474.07% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.25 USD  1474.07%

Hoogste 4.25 USD

Laagste 4.25 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor India Globalization Capital Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over India Globalization Capital Inc

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.